Targeting Phenotypes to Cure Advanced Cancers
Our Mission Is to Be the First to Develop Fully Curative Approaches to Metastatic Cancer.
We are focused on developing drugs for the treatment and cure of otherwise incurable cancers using multi-component therapeutics to target transport phenotypes.
Unprecedented Efficacy
Unprecedented efficacy in treating metastatic cancer has been demonstrated in preclinical trials.
Peer-reviewed Research
Our research has been published in leading peer-reviewed scientific journals.
Patent Protected
Protected by a strong patent portfolio of our own intellectual property, and some licensed from Houston Methodist Research Institute & University of Texas Health Science Center at Houston.
About Us
BrYet Europe S.r.l. is the European branch of BrYet US Inc., a privately-owned biotech company focused on the discovery and development of first-in-class therapies for primary or metastatic cancers of the lungs and liver.
Technology
Learn more about our research and technology.
News
Catch up on the latest news and more from BrYet.
Contact Us
Reach out for more information.